Artikel ; Online: In situ chemoimmunotherapy hydrogel elicits immunogenic cell death and evokes efficient antitumor immune response.
Journal of translational medicine
2024 Band 22, Heft 1, Seite(n) 341
Abstract: Background: Chemoimmunotherapy has shown promising advantages of eliciting immunogenic cell death and activating anti-tumor immune responses. However, the systemic toxicity of chemotherapy and tumor immunosuppressive microenvironment limit the clinical ... ...
Abstract | Background: Chemoimmunotherapy has shown promising advantages of eliciting immunogenic cell death and activating anti-tumor immune responses. However, the systemic toxicity of chemotherapy and tumor immunosuppressive microenvironment limit the clinical application. Methods: Here, an injectable sodium alginate hydrogel (ALG) loaded with nanoparticle albumin-bound-paclitaxel (Nab-PTX) and an immunostimulating agent R837 was developed for local administration. Two murine hepatocellular carcinoma and breast cancer models were established. The tumor-bearing mice received the peritumoral injection of R837/Nab-PTX/ALG once a week for two weeks. The antitumor efficacy, the immune response, and the tumor microenvironment were investigated. Results: This chemoimmunotherapy hydrogel with sustained-release character was proven to have significant effects on killing tumor cells and inhibiting tumor growth. Peritumoral injection of our hydrogel caused little harm to normal organs and triggered a potent antitumor immune response against both hepatocellular carcinoma and breast cancer. In the tumor microenvironment, enhanced immunogenic cell death induced by the combination of Nab-PTX and R837 resulted in 3.30-fold infiltration of effector memory T cells and upregulation of 20 biological processes related to immune responses. Conclusions: Our strategy provides a novel insight into the combination of chemotherapy and immunotherapy and has the potential for clinical translation. |
---|---|
Mesh-Begriff(e) | Mice ; Animals ; Hydrogels/pharmacology ; Hydrogels/therapeutic use ; Imiquimod/pharmacology ; Imiquimod/therapeutic use ; Carcinoma, Hepatocellular ; Immunogenic Cell Death ; Cell Line, Tumor ; Liver Neoplasms/drug therapy ; Immunotherapy/methods ; Immunity ; Tumor Microenvironment ; Nanoparticles |
Chemische Substanzen | Hydrogels ; Imiquimod (P1QW714R7M) |
Sprache | Englisch |
Erscheinungsdatum | 2024-04-09 |
Erscheinungsland | England |
Dokumenttyp | Journal Article |
ZDB-ID | 2118570-0 |
ISSN | 1479-5876 ; 1479-5876 |
ISSN (online) | 1479-5876 |
ISSN | 1479-5876 |
DOI | 10.1186/s12967-024-05102-0 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.